Onkologie. 2025:19(2):91-99 | DOI: 10.36290/xon.2025.019

Venous access in oncology - the choice between PICC and port

Viktor Maňásek
Komplexní onkologické centrum a Kanylační centrum Nemocnice Agel, Nový Jičín
Společnost pro porty a permanentní katétry, Praha

The choice of an adequate venous access in oncology is essential for an optimally mana­ged anticancer treatment, if parenteral administration is necessary. The treatment is usually longterm with the need to prefer to introduce such a venous access that offers the maximum benefits for the patient. It is not only a matter of safe introduction, taking into account the type and duration of the treatment, the patient's general condition, including comorbidities, and the quality of the venous system, but also a strategy for the care of the venous access device during its use. Education of the patient and his preferences are very important. In practice, we most often deal with the situation of whether to indicate a PICC or a venous port. In some situations, the indication for a specific type of venous access is clear, but sometimes the choice of both types of access overlaps. However, according to the defined criteria mentioned in the text, we are able to prefer the optimal venous access for individual clinical diagnoses. With regard to the expansion of the availability of ultrasound, navigation methods and a wide portfolio of venous access as well as fixation methods and aids for nursing care, we have the opportunity to provide the patient with venous access, which will bring maximum benefit while reducing possible complications.

Keywords: anticancer treatment, PICC, chest port, PICC-port, chemotherapy, venou access device choice.

Accepted: April 25, 2025; Published: May 2, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Maňásek V. Venous access in oncology - the choice between PICC and port. Onkologie. 2025;19(2):91-99. doi: 10.36290/xon.2025.019.
Download citation
PDF will be unlocked 2.5.2026

References

  1. Duggan C, Hernon O, Dunne R, et al. Vascular access device type for systemic anti-cancer therapies in cancer patients: A scoping review. Crit Rev Oncol Hematol. 2024;196:104277. doi: 10.1016/j.critrevonc.2024.104277. Epub 2024 Mar 14. PMID: 38492760. Go to original source... Go to PubMed...
  2. Maňásek V, Charvát J, Chovanec V, et al. Indications for venous access in oncology - recommendations of national professional societies and current state in the Czech Republic. Klin Onkol. 2021;34(3):192-201. English. doi: 10.48095/ccko2021192. PMID: 34362255. Go to original source... Go to PubMed...
  3. Vokurka S, Maňásek V, Hrabánková Navrátilová D,et al. Extravasation (paravasation) of chemotherapy drugs - updated recommendations (2020) for standard care in the Czech Republic from the cooperation of the Supportive Care Group of the Czech Society for Oncology, Czech Society for Hematology, Oncology Section of the Czech Nurses Association and the Society for Ports and Permanent Catheters. Klin Onkol. 2020;33(5):390-395. English. doi: 10.14735/amko2020390. PMID: 33108885. Go to original source... Go to PubMed...
  4. Brescia F, Pittiruti M, Spencer T, et al. The SIP protocol update: Eight strategies, incorporating Rapid Peripheral Vein Assessment (RaPeVA), to minimize complications associated with peripherally inserted central catheter insertion. J Vasc Access. 2024;25(1):5-13. doi: 10.1177/11297298221099838. Epub 2022 May 27. PMID: 35633065; PMCID: PMC10845830. Go to original source... Go to PubMed...
  5. Spencer TR, Pittiruti M. Rapid Central Vein Assessment (RaCeVA): A systematic, standardized approach for ultrasound assessment before central venous catheterization. J Vasc Access. 2019;20(3):239-249. doi: 10.1177/1129729818804718. Epub 2018 Oct 4. PMID: 30286688. Go to original source... Go to PubMed...
  6. Brescia F, Pittiruti M, Ostroff M, et al. Rapid Femoral Vein Assessment (RaFeVA): A systematic protocol for ultrasound evaluation of the veins of the lower limb, so to optimize the insertion of femorally inserted central catheters. J Vasc Access. 2021;22(6):863-872. doi: 10.1177/1129729820965063. Epub 2020 Oct 16. PMID: 33063616. Go to original source... Go to PubMed...
  7. Tesařová P, Karetová D, Hirmerová J, Malý R, et al. Prevence, diagnostika a léčba trombózy spojené se zhoubným nádorem Transfuze Hematol. Dnes. 2023;29(1):61-67, doi: https://doi.org/10.48095/cctahd202361. Go to original source...
  8. Bertoglio S, Cafiero F, Meszaros P, et al. PICCPORT totally implantable vascular access device in breast cancer patients undergoing chemotherapy. J Vasc Access. 2020;21(4):460-466. doi: 10.1177/1129729819884482. Epub 2019 Nov 1. PMID: 31674857. Go to original source... Go to PubMed...
  9. Moss JG, Wu O, Bodenham AR, et al. Central venous access devices for the delivery of systemic anticancer therapy (CAVA): a randomised controlled trial. Lancet. 2021;398(10298):403-415. doi: 10.1016/S01406736(21)00766-2. Epub 2021 Jul 21. PMID: 34297997. Go to original source...
  10. Annetta MG, Bertoglio S, Biffi R, et al. Management of antithrombotic treatment and bleeding disorders in patients requiring venous access devices: A systematic review and a GAVeCeLT consensus statement. J Vasc Access. 2022;23(4):660-671. doi: 10.1177/11297298211072407. Epub 2022 May 9. PMID: 35533088. Go to original source... Go to PubMed...
  11. Pironi L, Boeykens K, Bozzetti F,et al. ESPEN practical guideline: Home parenteral nutrition. Clin Nutr. 2023;42(3):411-430. doi: 10.1016/j.clnu.2022.12.003. Epub 2023 Jan 9. PMID: 36796121. Go to original source... Go to PubMed...
  12. Sousa B, Furlanetto J, Hutka M, et al. Central venous access in oncology: ESMO Clinical Practice Guidelines. Ann Oncol. 2015;26 Suppl 5: v152-168. doi: 10.1093/annonc/mdv296. PMID: 26314776. Go to original source... Go to PubMed...
  13. Gonella S, Antonuzzo A, Bossi P. Peripherally or centrally inserted central catheters: what is the best vascular access device for cancer patients? Support Care Cancer. 2021;29(6):2803-2806. doi: 10.1007/s00520-021-06032-z. Epub 2021 Jan 29. PMID: 33515107. Go to original source... Go to PubMed...
  14. Mielke D, Wittig A, Teichgräber U. Peripherally inserted central venous catheter (PICC) in outpatient and inpatient oncological treatment. Support Care Cancer. 2020;28(10):4753-4760. doi: 10.1007/s00520-019-05276-0. Epub 2020 Jan 22. PMID: 31970514; PMCID: PMC7447660. Go to original source... Go to PubMed...
  15. Wang K, Zhong J, Huang N, Zhou Y. Economic evaluation of peripherally inserted central catheter and other venous access devices: A scoping review. J Vasc Access. 2020;21(6):826-837. doi: 10.1177/1129729819895737. Epub 2020 Jan 2. PMID: 31894710. Go to original source... Go to PubMed...
  16. Shao G, Zhou X, Zhang S, et al. Cost-utility analysis of centrally inserted totally implanted access port (PORT) vs. peripherally inserted central catheter (PICC) in the oncology chemotherapy. Front Public Health. 2022;10:942175. doi: 10.3389/fpubh.2022.942175. PMID: 35937250; PMCID: PMC9354617. Go to original source... Go to PubMed...
  17. Wang P, Soh KL, Ying Y, et al. Risk of VTE associated with PORTs and PICCs in cancer patients: A systematic review and meta-analysis. Thromb Res. 2022;213:34-42. doi: 10.1016/j.thromres.2022.02.024. Epub 2022 Mar 7. PMID: 35279504. Go to original source... Go to PubMed...
  18. Sun Y, Wu X. Complications of implanted port catheters and peripherally inserted central catheters in chemotherapy-treated cancer patients: A meta-analysis. Adv Clin Exp Med. 2023;32(5):523-532. doi: 10.17219/acem/156346. PMID: 36530028. Go to original source... Go to PubMed...
  19. Bertoglio S, Annetta MG, Brescia F, et al. A multicenter retrospective study on 4480 implanted PICC-ports: A GAVeCeLT project. J Vasc Access. 2022 Jan 17:11297298211067683. doi: 10.1177/11297298211067683. Epub ahead of print. PMID: 35034480. Go to original source... Go to PubMed...
  20. Brescia F, Annetta MG, Pinelli F, et al. A GAVeCeLT bundle for PICC-port insertion: The SIP-Port protocol. J Vasc Access. 2023 Nov 13:11297298231209521. doi: 10.1177/11297298231209521. Epub ahead of print. PMID: 37953715. Go to original source... Go to PubMed...
  21. Clatot F, Fontanilles M, Lefebvre L, et al. Randomised phase II trial evaluating the safety of peripherally inserted catheters versus implanted port catheters during adjuvant chemotherapy in patients with early breast cancer. Eur J Cancer. 2020;126:116-124. doi: 10.1016/j.ejca.2019.11.022. Epub 2020 Jan 10. PMID: 31931269. Go to original source... Go to PubMed...
  22. Pinelli F, Barbani F, Defilippo B, et al. Quality of life in women with breast cancer undergoing neoadjuvant chemotherapy: comparison between PICC and PICC-port. Breast Cancer. 2024 Jul 9. doi: 10.1007/s12282-024-01608-z. Epub ahead of print. PMID: 38980572. Go to original source... Go to PubMed...
  23. Fankhauser CD, Oldenburg J, Albers P, et al. Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021. Eur Urol. 2021;80(1):4-6. doi: 10.1016/j.eururo.2021.02.032. Epub 2021 Mar 12. PMID: 33722419. Go to original source... Go to PubMed...
  24. Haugnes HS, Negaard HF, Jensvoll H, et al. Thromboembolic Events During Treatment with Cisplatin-based Chemotherapy in Metastatic Testicular Germ-cell Cancer 2000-2014: A Population-based Cohort Study. Eur Urol Open Sci. 2021; 32:19-27. doi: 10.1016/j.euros.2021.07.007. PMID: 34667955; PMCID: PMC8505199. Go to original source... Go to PubMed...
  25. Ozgun G, Haney L, Kern S, et al. Once Upon a Time… Simple, Sensible Management of Venous Access for Chemotherapy Delivery in Germ Cell Tumors. JCO Oncol Pract. 2024;20(3):309-310. doi: 10.1200/OP.23.00730. Epub 2024 Jan 26. PMID: 38277617. Go to original source... Go to PubMed...
  26. Tran B, Ruiz-Morales JM, Gonzalez-Billalabeitia E, et al. Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3). Cancer Med. 2020;9(1):116-124. doi: 10.1002/cam4.2674. Epub 2019 Nov 12. PMID: 31715650; PMCID: PMC6943085. Go to original source... Go to PubMed...
  27. Vertakova-Krakovská B, Maňásek V, Kunderlík M, et al. Is there an increased risk of PICC-related deep vein thrombosis in patients with testicular cancer undergoing platinum-based chemotherapy? An International Retrospective Evaluation. Prague 2024; Poster WoCoVA.
  28. Wiesen B, Atwell M, Leavitt C, et al. Use of Peripheral Intravenous Access in Patients Undergoing Chemotherapy for Testicular Cancer. JCO Oncol Pract. 2024;20(3):361-369. doi: 10.1200/OP.23.00580. Epub 2023 Dec 21. PMID: 38127812. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.